Expression and clinical significance of HIST1H2BH in head and neck squamous cell carcinoma

doi:10.19439/j.sjos.2021.06.008

Abstract

Abstract: PURPOSE: The purpose of this study was to investigate the expression of HIST1H2BH in head and neck squamous cell carcinoma (HNSCC) and to analyze its clinical significance. METHODS: The expression of HIST1H2BH in different tumors and HNSCC were analyzed based on the Oncomine and GEPIA database, and its relationship with clinicopathological parameters and prognostic value of HNSCC patients were also analyzed. The expression of HIST1H2BH in clinical specimens were detected by immunohistochemical staining. The variation of HIST1H2BH in HNSCC and its relationship with prognosis were analyzed based on the cBioPortal database. The interaction proteins and molecular mechanism of HIST1H2BH were preliminarily predicted using the String database. SPSS 24.0 software package was used for statistical analysis of the data. RESULTS: Analysis of Oncomine database and GEPIA database showed that HIST1H2BH was highly expressed in variety of tumors, and was significantly highly expressed in HNSCC. The expression level of HIST1H2BH was closely related to the pathological stage and prognosis of HNSCC patients, the prognosis of patients with high HIST1H2BH expression was poor. Immunohistochemical results of clinical specimens showed that the expression of HIST1H2BH in the cancerous tissue of HNSCC patients was significantly higher than that in the adjacent tissues. cBioPortal database analysis showed that the variation rate of HIST1H2BH in HNSCC patients was not high, but it was related to the disease-free survival rate. String database analysis showed that there were many genes associated with HIST1H2BH, and the signal pathways involved in biological processes were also complex. CONCLUSIONS: The expression of HIST1H2BH is elevated in HNSCC tissues, and its high expression is associated with poor prognosis. HIST1H2BH could be served as a marker for diagnosis and prognosis of HNSCC.

Key words: HIST1H2BH, Head and neck, Squamous cell carcinoma, Database analysis, Prognosis

CLC Number:

R739.8

WANG Shou-peng, DING Zi-xue, MENG Jian, LI Meng, LI Xiao-dong, YUAN Zhuang. Expression and clinical significance of HIST1H2BH in head and neck squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2021, 30(6): 599-605.

References

[1] Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
[2] Husain N, Neyaz A.Human papillomavirus associated head and neck squamous cell carcinoma: controversies and new concepts[J]. J Oral Biol Craniofac Res, 2017, 7(3): 198-205.
[3] Esteller M.Cancer epigenomics: DNA methylomes and histone-modification maps[J]. Nat Rev Genet, 2007,8(4): 286-298.
[4] Berdasco M, Esteller M.Aberrant epigenetic landscape in cancer: how cellular identity goes awry[J]. Dev Cell, 2010, 19(5): 698-711.
[5] Dawson MA, Kouzarides T.Cancer epigenetics: from mechanism to therapy[J]. Cell, 2012, 150(1): 12-27.
[6] Hema KN, Smitha T, Sheethal HS, et al.Epigenetics in oral squamous cell carcinoma[J]. J Oral Maxillofac Pathol, 2017, 21(2): 252-259.
[7] Bennett RL, Bele A, Small EC, et al.A mutation in histone H2B represents a new class of oncogenic driver[J]. Cancer Discov, 2019,9(10):1438-1451.
[8] Li X, Tian R, Gao H, et al.Identification of a histone family gene signature for predicting the prognosis of cervical cancer patients[J]. Sci Rep, 2017, 7(1): 16495.
[9] Schlingemann J, Habtemichael N, Ittrich C, et al.Patient-based cross-platform comparison of oligonucleotide microarray expression profiles[J]. Lab Invest, 2005, 85(8): 1024-1039.
[10] Pyeon D, Newton MA, Lambert PF, et al.Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers[J]. Cancer Res, 2007, 67(10): 4605-4619.
[11] Stucky A, Sedghizadeh PP, Mahabady S, et al.Single-cell genomic analysis of head and neck squamous cell carcinoma[J]. Oncotarget, 2017, 8(42): 73208-73218.
[12] Leemans CR, Braakhuis BJ, Brakenhoff RH.The molecular biology of head and neck cancer[J]. Nat Rev Cancer, 2011, 11(1): 9-22.
[13] Lampri ES, Chondrogiannis G, Ioachim E, et al.Biomarkers of head and neck cancer, tools or a gordian knot?[J]. Int J Clin Exp Med, 2015, 8(7): 10340-10357.
[14] Van Waes C, Musbahi O.Genomics and advances towards precision medicine for head and neck squamous cell carcinoma[J]. Laryngoscope Investig Otolaryngol, 2017, 2(5): 310-319.
[15] Jenuwein T, Allis CD.Translating the histone code[J]. Science, 2001, 293(5532): 1074-1080.
[16] Nacev BA, Feng L, Bagert JD, et al.The expanding landscape of 'oncohistone' mutations in human cancers[J]. Nature, 2019, 567(7749): 473-478.
[17] Monteiro FL, Vitorino R, Wang J, et al.The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelial-mesenchymal transition in mammary epithelial and in breast cancer cells[J]. Cancer Lett, 2017, 396(1): 42-52.
[18] Bhattacharya S, Reddy D, Jani V, et al.Histone isoform H2A1H promotes attainment of distinct physiological states by altering chromatin dynamics[J]. Epigenetics Chromatin, 2017,10(1):48-56.
[19] Chen YW, Kao SY, Wang HJ, et al.Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma[J]. Cancer, 2013, 119(24): 4259-4267.
[20] Le JM, Squarize CH, Castilho RM.Histone modifications: Targeting head and neck cancer stem cells[J]. World J Stem Cells, 2014, 6(5): 511-525.
[21] Leipold A, Hess J, Zaoui K.The epigenome. Target for innovative therapies in head and neck carcinoma[J]. HNO, 2015, 63(11):786-791.